Ultragenyx Pharmaceutical | RARE - Ordinary Share Capital


Ultragenyx Pharmaceutical reported $98.3M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Alnylam Pharmaceuticals USD 133.44M 1.07M Mar/2026
BioCryst Pharmaceuticals USD 213.06M 2.54M Dec/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Esperion Therapeutics USD 245.22M 39.79M Dec/2025
Immunic USD 120.38M 21.73M Dec/2025
Insmed USD 216.52M 2.27M Mar/2026
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
Karyopharm Therapeutics USD 18.31M 18.3M Dec/2025
Kyowa Hakko Kirin JPY 523.49M 1000 Mar/2026
MacroGenics USD 63.32M 60K Dec/2025
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 100.6M 500K Mar/2026
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Sarepta Therapeutics USD 105.57M 607K Mar/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vertex Pharmaceuticals USD 254.2M 200K Mar/2026
Xoma USD 87K 1000 Jun/2024